Publications by authors named "Mei-Ying Long"
Article Synopsis
- The study aimed to compare the outcomes of radiation-induced hepatic toxicity (RIHT) in patients with hepatocellular carcinoma (HCC) receiving radiotherapy (RT) combined with anti-PD1 antibodies versus RT alone, and to identify factors predicting non-classic radiation-induced liver disease (ncRILD).
- Patients with unresectable HCC were retrospectively analyzed, with 30 receiving RT plus anti-PD1 and 66 receiving RT alone, using propensity score matching to ensure comparability.
- Results indicated similar RIHT rates between the two groups, with a higher frequency of elevated AST levels in the RT + PD1 group after matching; a nomogram was developed based on factors such as tumor number and patient age,
Article Synopsis
- The study focuses on non-classic radiation-induced liver disease (ncRILD) after intensity-modulated radiotherapy (IMRT) in patients with Child-Pugh grade B (CP-B) hepatocellular carcinoma (HCC).
- Among the 75 patients evaluated, 22.7% experienced ncRILD, with specific measurements of liver function and tumor characteristics noted.
- A nomogram was developed to predict the likelihood of ncRILD based on pre-treatment prothrombin time, number of tumors, and average liver dose during treatment, showing strong predictive accuracy.
Article Synopsis
- Intensity-modulated radiotherapy (IMRT) is a treatment option for patients with unresectable hepatocellular carcinoma (uHCC), and the study investigates how immune parameters can predict patient survival.
- * The research analyzed clinical data from 309 uHCC patients, finding that higher platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and systemic immune inflammation (SII) after treatment correlated with poorer survival outcomes.
- * A prognostic nomogram was created from the findings, successfully predicting 3- and 5-year survival rates, with validation showing its effectiveness in a separate patient group.
Background: The combination of transcatheter arterial chemoembolization (TACE) plus sorafenib prolonged progression-free survival (PFS) and overall survival (OS) than sorafenib or TACE monotherapy for patients with hepatocellular carcinoma (HCC). This study assessed the efficacy and safety of radiotherapy (RT) plus monoclonal antibody against programmed cell death 1 (anti-PD1) versus TACE plus sorafenib for patients with advanced HCC.
Methods: Patients with advanced HCC who treated with RT plus anti-PD1 and TACE plus sorafenib were enrolled.